|Bid||0.1050 x 1269100|
|Ask||0.1150 x 90000|
|Day's range||0.1100 - 0.1200|
|52-week range||0.1100 - 0.3475|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||26 Apr 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.57|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Over the last year, a good number of insiders have significantly increased their holdings in KGL Resources Limited...
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance socia
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company,